Immunic, Inc. · NASDAQ:IMUX

Immunic — Technical Presentation (February 2023)

65 slides from Immunic's technical presentation, Feb 9, 2023

  1. Slide 1: Celiac Disease R&D Webcast

    Celiac Disease R&D Webcast Current Pathways for Drug Development & Persistent Disease Activity Despite Gluten-Free Diet as the Unmet Medical Need NASDAQ: IMUX | February 9, 2023

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

  3. Slide 3: Agenda: Celiac Disease R&D Webcast

    Agenda: Celiac Disease R&D Webcast Treatment of Celiac Disease: Current Pathways for Drug Development & Persistent Disease Activity Despite Gluten-Free Diet as the Unmet Medical Need Mechanism of Action and 01 11:00 – 11:05 Welcome and Introductions 06 11:55 – 12:05 Preclinical Data for IMU-856 Expe

  4. Slide 4: Welcome and Introductions

    01 Celiac Disease R&D Webcast Welcome and Introductions

  5. Slide 5: Speakers: Celiac Disease R&D Webcast

    Speakers: Celiac Disease R&D Webcast Featured Experts Immunic Speakers Joseph A. Murray, MD Daniel Vitt, PhD Co-Founder Professor of Medicine Chief Executive Officer & President Director, Celiac Disease Research John and Shirley Berry Professor of Gastrointestinal Sciences Division of Gastroenterolo

  6. Slide 6: Advanced Clinical Pipeline

    Advanced Clinical Pipeline Three Differentiated Programs in Various Phases of Clinical Development Program Target Preclinical Phase 1 Phase 2 Phase 3 Key Milestones § Interim analysis of CALLIPER trial in PMS Relapsing Multiple Sclerosis (RMS) – ENSURE Trials planned after half of the patients Vidof

  7. Slide 7: Introduction to Celiac Disease

    02 Introduction to Celiac Disease Prevalence Disease Overview and Diagnosis

  8. Slide 8: Introduction to Celiac Disease

    02 Introduction to Celiac Disease Prevalence Disease Overview and Diagnosis

  9. Slide 9: Celiac Disease is a Serious Life-Long Autoimmune Disease

    Celiac Disease is a Serious Life-Long Autoimmune Disease § Celiac disease is a multifactorial, complex autoimmune disease caused by an immune reaction against a gluten protein gut lumen degradation product of gluten and strongly associated with specific HLA class II gene variants (HLA-DQ2/-DQ8)[1] g

  10. Slide 10: Celiac Disease Currently Has No Adequate Treatment Options

    Celiac Disease Currently Has No Adequate Treatment Options How much is 10 mg of gluten? The Only Option Today is a Gluten-Free Diet[1] Like a pin-point § The only established therapeutic option is a life-long strict adherence of flour to a gluten-free diet, which involves complete avoidance of prote

  11. Slide 11: Ongoing Active Celiac Disease Despite Gluten-Free Diet as Unmet Medical Need

    Ongoing Active Celiac Disease (OACD) Despite Gluten-Free Diet (GFD) as Unmet Medical Need High Risk of Accidental, Ongoing Active Unmet Inadvertent Gluten Intake Celiac Disease Medical Need Most studies report between 24 % and 47 %[1-6] These OACD patients of patients with signs and Wide gluten cros

  12. Slide 12: Persistent Villous Atrophy Despite Gluten-Free Diet is Common

    Persistent Villous Atrophy Despite Gluten-Free Diet is Common Most Studies Report Rates of Persistent Villous Atrophy Between 24 % and 47 % Percentage of Persistent Villous Atrophy Despite ≥ 12 Months Gluten-Free Diet (% of total celiac disease patients) 100% 80% 60% 40% Average 20% 43.0% 44.0% 47.0

  13. Slide 13: Celiac Disease is Not Restricted to the Small Intestine

    Celiac Disease is Not Restricted to the Small Intestine and Results in Serious Consequences Clinical Findings § Dementia[1] § Dental enamel § Recurring headaches and Consequences hypoplasia § Peripheral neuropathy § Dermatitis herpetiformis § Short stature § Recurrent aphthous § Epilepsy and seizure

  14. Slide 14: Signs and Symptoms in Ongoing Active Celiac Disease

    Signs and Symptoms in Ongoing Active Celiac Disease (OACD) Ongoing Exposure to Gluten Single Dose 3 – 7 Days 2 – 6 Weeks 6 Weeks – 1 Year Enterocyte/villous Enterocyte/villous damage, Gastrointestinal damage, steatorrhea, Nausea, vomiting, diarrhea, dysmotility, weight loss, weight loss, symptoms, m

  15. Slide 15: Introduction to Celiac Disease

    02 Introduction to Celiac Disease Prevalence and Disease Overview Diagnosis

  16. Slide 16: Celiac Disease is a Major Public Health Problem Worldwide

    Celiac Disease is a Major Public Health Problem Worldwide A Systematic Review and Meta-Analysis of 96 Articles Published Between 1991 and 2016 Showed a Pooled Worldwide Prevalence of 1.4 % Based on Blood Tests[1] § Pooled seroprevalence of celiac disease in different continents ranged from 1.1% (95%

  17. Slide 17: Celiac Disease Can Develop at Any Age With Often Delayed Diagnosis

    Celiac Disease Can Develop at Any Age With Often Delayed Diagnosis The Median Age of Diagnosis is 40 Years Diagnosis is Often Delayed Due to With a Modest Female Predominance[1,2] Non-Classical/Extra-Intestinal Symptoms > 80 years Study Diagnostic Delay (4 %) 60-79 years Swiss survey, N=1689[3] Aver

  18. Slide 18: Overlap in Disease Symptoms Contributes to Diagnostic Delay

    Overlap in Disease Symptoms Contributes to Diagnostic Delay in Celiac Disease Patients Celiac Disease Food Intolerance Microscopic Colitis Crohn’s Disease Irritable Bowel Syndrome Caio et al. BMC Medicine (2019) 17:142 18 | © Immunic, Inc. | Feb/09/2023

  19. Slide 19: Diagnostic Approach in Suspected Celiac Disease

    Diagnostic Approach in Suspected Celiac Disease 1. Serology 2. Biopsy a. Celiac serology[1] b. Serology can be unreliable § Confirmatory small intestinal if GFD is followed[1] biopsy[1] Tissue Tissue § Supplementary tests are Transglutaminase- Transglutaminase- either gluten challenge or IgA IgA (tT

  20. Slide 20: Diagnosis of Celiac Disease: What Histology Tells Us

    Diagnosis of Celiac Disease: What Histology Tells Us A Well Controlled Celiac Disease B Ongoing Active Celiac Disease (OACD) § Tip-predominant intraepithelial lymphocytosis § Villous height:Crypt depth ratio alone (see arrow) § Intraepithelial Lymphocytes Figure and Text: Kamboj et al., Clinical and

  21. Slide 21: Diagnosis of Celiac Disease: What Histology Tells Us

    Diagnosis of Celiac Disease: What Histology Tells Us Schematic Depiction of Marsh- Histological Description Q-Marsh Conversion Table for Formalin Fixed Samples (PAXgene Fixed) Oberhuber Grades I-III Marsh Villous IEL Villi Crypts Oberhuber height:Crypt (CD3+ / 100 0 I II IIIa IIIb IIIc class depth r

  22. Slide 22: Celiac Disease Treatment Landscape

    Celiac Disease 03 Treatment Landscape Investigational Growing Interest Regulatory Guidelines and Treatments in by Pharma Development Development Industry Pathways

  23. Slide 23: Celiac Disease Treatment Landscape

    Celiac Disease 03 Treatment Landscape Investigational Growing Interest Regulatory Guidelines and Treatments in by Pharma Development Development Industry Pathways

  24. Slide 24: No Approved Drugs Exist Today; Therapeutics in Development

    No Approved Drugs Exist Today; Therapeutics Are in Development Across the Spectrum of Celiac Disease Drivers Celiac Disease Barrier Insult Immune Response Components Damage Reduce Increase Therapeutic Reduce barrier Immune Immuno- Barrier Modify gluten immune Approaches permeability activation/ supp

  25. Slide 25: Gluten Modification in the Lumen (Latiglutenase)

    Gluten Modification in the Lumen (Latiglutenase) Restricted to Patients With Ongoing Gluten Exposure Study Phase 2b, CeliAction Study (NCT01917630)[1,2] Phase 2, CeliacShieldTM Study (NCT03585478)[3] Gluten Challenge § None, OACD patients § 2 g gluten challenge daily for 6 weeks § No greater improve

  26. Slide 26: Inhibition of Transglutaminase 2 (ZED1227/TAK-1227)

    Inhibition of Transglutaminase 2 (ZED1227/TAK-1227) Protects Against Gluten-Induced Epithelial Damage Study Phase 2b Study (EudraCT number 2020-004612-97) Phase 2a Study (EudraCT number 2017-002241-30)[1] Gluten Challenge § None, OACD patients § 3 g gluten challenge daily for 6 weeks § Improvement o

  27. Slide 27: IMU-856 Addresses Two Key Pathological Aspects of Celiac Disease

    IMU-856 Addresses Two Key Pathological Aspects of Celiac Disease – Applicable for Other Inflammatory Bowel Indications IMU-856 Mode of Action Orally available and systemically acting small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier fun

  28. Slide 28: Intestinal Barrier Function is a Therapeutic Target Beyond Celiac Disease

    Intestinal Barrier Function is a Therapeutic Target Beyond Celiac Disease Compromised intestinal barrier function has been associated not only with celiac disease but with a number of disease states, both intestinal and systemic Crohn’s disease: low bowel permeability has better IBS-D: bowel permeab

  29. Slide 29: Celiac Disease Treatment Landscape

    Celiac Disease 03 Treatment Landscape Investigational Growing Interest Regulatory Guidelines and Treatments in by Pharma Development Development Industry Pathways

  30. Slide 30: Pharma Industry Has Become Active in the Celiac Disease Space

    Pharma Industry Has Become Active in the Celiac Disease Space Company KAN-101 ZED1227 PRV-015 Program (intravenous) (oral) (IL-15 monoclonal antibody) Stage at Time Phase 1b/2 Phase 2b Phase 2b of Deal ready ongoing ready Year 2022 2022 2018 30 | © Immunic, Inc. | Feb/09/2023

  31. Slide 31: Unmet Medical Need

    Highly Underserved Therapeutic Area No drug treatments Permanent available Persistent symptoms villous High Complements presence prevalence commercial atrophy gastrointestinal Significant presence Serious disease complications burden Gluten-Free Diet not Clear sufficient development pathway Unmet Me

  32. Slide 32: Celiac Disease Treatment Landscape

    Celiac Disease 03 Treatment Landscape Investigational Growing Interest Regulatory Guidelines and Treatments in by Pharma Development Development Industry Pathways

  33. Slide 33: Regulatory Guidelines and Development Pathways

    Regulatory Guidelines and Development Pathways Two Recent Important FDA Guidances for Drug Development FDA Workshop on Celiac Disease FDA Draft Guidance July 22, 2021[1] April 2022[2] Gastroenterology Regulatory Endpoints Celiac Disease: Developing Drugs for Adjunctive Treat- and the Advancement of

  34. Slide 34: FDA Draft Guidance April 2022

    FDA Draft Guidance April 2022 Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet Recommended Trial Recommended Trial Design Recommended Efficacy Assessments Population Adults with OACD Randomized, double blind, placebo-controlled design Goals of treatment in patients wit

  35. Slide 35: Gluten Challenge as Important Tool in Early Clinical Development

    Gluten Challenge as Important Tool in Early Clinical Development FDA Workshop on Celiac Disease, July 22, 2021 - Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI): Study subjects: Screening Run-out/ Well-controlled celiac disease Safety follow up Duodenal biopsy

  36. Slide 36: Interleukin-2 (IL-2) Response Following Gluten Ingestion

    04 IL-2, a Biomarker to Measure Treatment Effects? Interleukin-2 (IL-2) Response Following Gluten Ingestion

  37. Slide 37: Interleukin-2: An Emerging Biomarker to Gluten Exposure

    Interleukin-2: An Emerging Biomarker to Gluten Exposure Gluten 3 g Gluten 10 g § Main source for IL-2: IL-2 (pg/mL) activated gluten- specific CD4+ T cells[1] § IL-2 response is gluten dose dependent[2] à the more gliadin crosses epithelial barrier, the higher the gluten-specific CD4+ T cell respons

  38. Slide 38: Interleukin-2 Correlates With Onset and Severity of Symptoms

    Interleukin-2 Correlates With Onset and Severity of Symptoms Serum Interleukin-2 elevations correlate with onset and severity of symptoms after gluten exposure in patients with celiac disease[1] Elevated as early as 2 hours post gluten challenge (peak level at 4 hours)[2] Figure Ref [1] [1] Tye-Din

  39. Slide 39: Joseph A. Murray, MD

    05 Expert Presentation Joseph A. Murray, MD Professor of Medicine Director, Celiac Disease Research John and Shirley Berry Professor of Gastrointestinal Sciences Division of Gastroenterology and Hepatology Department of Internal Medicine Mayo Clinic, Rochester, MN

  40. Slide 40: Joseph A. Murray, MD

    Joseph A. Murray, MD Professor of Medicine Focus of Today’s Presentation Director, Celiac Disease Research § Role of the innate and adaptive immune system in celiac disease John and Shirley Berry Professor of Gastrointestinal Sciences § Relevance of the pro-inflammatory cytokine IL-2 as objective bi

  41. Slide 41: Mechanism of Action and Preclinical Data for IMU-856

    Mechanism of Action and 06 Preclinical Data for IMU-856 Tightness of the Regeneration of Target Barrier the Barrier

  42. Slide 42: IMU-856's Target is Expressed in Colon and Small Intestine

    IMU-856’s Target is Expressed in Colon and Small Intestine Target is Predominantly Expressed in Intestinal Epithelial Cells in Intestinal Crypts Colon – murine Small intestine – murine Colon – IBD patient – Lumen Villus Lumen inflamed tissue Crypts Target Crypts Target Epithelial cell marker EpCAM N

  43. Slide 43: IMU-856 Exhibits High Selectivity Over Other Protein Family Members

    IMU-856 Exhibits High Selectivity Over Other Protein Family Members IMU-856 potently inhibits the target’s enzyme activity with an IC50 of 15 nM in a biochemical assay SubT1 SubT2 As typical for epigenetic targets, the inhibition of SubT3 the enzyme activity by IMU-856 is even more SubT4 pronounced

  44. Slide 44: IMU-856 Improves Intestinal Barrier Function

    IMU-856 Improves Intestinal Barrier Function Intestinal permeability was measured as TEER after TNF⍺ barrier-disrupting stimulation in Caco-2 cells **** #### 160 $$ Relative recovery rate 140 120 100 80 75 50 25 0 DMSO 0.1 0.3 1 3 IMU-856 (µM) 48 hours of TNF⍺ challenge followed by 144 hours of IMU-

  45. Slide 45: Initial Hypothesis: IMU-856 Impacts Tight Junction Protein Expression

    Initial Hypothesis: IMU-856 Impacts Tight Junction Protein Expression IMU-856 Downregulation[1] Upregulation[2] Upregulation Downregulation Claudin-1 Claudin-2 Claudin-1 Claudin-2 IL-6 - + + + IMU-856 (µM) - - 1 3 Relocation of ZO-1 Leaky gut Claudin-1 away from the TJ upper Claudin-2 lower Disrupti

  46. Slide 46: IMU-856 Treatment Results in More Normal Crypts in DSS Colitis Model

    IMU-856 Treatment Results in More Normal Crypts in DSS Colitis Model IMU-856 treatment during onset of colitis in a DSS model Vehicle preserves more normal crypts and improves regeneration IMU-856 1 mg/kg Crypts: Normal Hypertrophic Atophic Wang et al., 2019, Cell DSS: dextran sulfate sodium 46 | ©

  47. Slide 47: Renewal of Intestinal Crypt Cells Enables Regeneration of Gut Architecture

    Renewal of Intestinal Crypt Cells Enables Regeneration of Gut Architecture after Damage Repair of the gut architecture after damage is driven Treatment with IMU-856 slightly induced the renewal by renewal of epithelial intestinal crypt cells of intestinal epithelial cells in a murine DSS model and s

  48. Slide 48: Michael Schumann, MD

    07 Expert Presentation Michael Schumann, MD Attending Physician in Internal Medicine and Gastroenterology Department of Gastroenterology, Infectious Diseases and Rheumatology Campus Benjamin Franklin Charité – Universitätsmedizin Berlin

  49. Slide 49: Michael Schumann, MD

    Michael Schumann, MD Attending Physician in Internal Medicine Focus of Today’s Presentation and Gastroenterology § Role of the intestinal barrier function in the Department of Gastroenterology, pathophysiology of celiac disease Infectious Diseases and Rheumatology § Research results from preclinical

  50. Slide 50: Q&A Session with the Two Experts

    08 Celiac Disease R&D Webcast Q&A Session with the Two Experts

  51. Slide 51: Clinical Overview for IMU-856

    09 Clinical Overview for IMU-856 Summary Phase 1 Ongoing Phase 1 SAD/MAD Data in Part C Trial in Healthy Subjects Celiac Disease

  52. Slide 52: Clinical Overview for IMU-856

    09 Clinical Overview for IMU-856 Summary Phase 1 Ongoing Phase 1 SAD/MAD Data in Part C Trial in Healthy Subjects Celiac Disease

  53. Slide 53: Phase 1 Clinical Trial: Trial Design and Current Status

    Phase 1 Clinical Trial: Trial Design and Current Status PART A PART B PART C Evaluation of Evaluation of multiple ascending Evaluation of patients with celiac single ascending doses (SAD) doses (MAD) disease receiving 28-day treatment of Healthy human subjects Healthy human subjects randomized IMU-8

  54. Slide 54: Dose-Linear Pharmacokinetics in Multiple Dosing

    Dose-Linear Pharmacokinetics in Multiple Dosing Part B, Multiple Ascending Doses, Day 1 and 14 § Terminal plasma half-life at steady state (Day 14 values) Mean plasma concentrations over time by treatment Part B (linear) 17 to 21 hours comparable to single dose § Linear pharmacokinetics also after m

  55. Slide 55: Pharmacokinetic Results: Trough Levels After Multiple Dosing

    Pharmacokinetic Results: Trough Levels After Multiple Dosing Part B, Multiple Ascending Doses Day 1 – Day 14: Favorable Pharmacokinetic Properties Mean plasma concentrations over time by treatment Part B (linear) for IMU-856 Day 15 – Day 17: Drop in plasma concentrations over time post treatment § F

  56. Slide 56: Overall Summary of TEAE, SAE and AE Severity

    Overall Summary of TEAE, SAE and AE Severity Part B, Multiple Ascending Doses Treatment Cohort 7N Cohort 8N Cohort 9N Active Placebo Category 40 mg 80 mg 160 mg (N=17) (N=6) (N=5) (N=6) (N=6) Once-daily 14-day Subjects with TEAEs, n (%) 4 (80%) 5 (83%) 4 (67%) 13 (76%) 5 (83%) Subjects with mild TEA

  57. Slide 57: Most Common Treatment-Emergent Adverse Events

    Most Common Treatment-Emergent Adverse Events Part B, Multiple Ascending Doses Number (%) of subjects with TEAEs occurring in more than 2 subjects [Number of TEAEs reported] Cohort 7N Cohort 8N Cohort 9N MedDRA 40 mg 80 mg 160 mg Active Placebo Once-daily oral (N=17) (N=6) Preferred Term (N=5) (N=6)

  58. Slide 58: Laboratory Parameters: No Hy's Law Cases Observed

    Laboratory Parameters: No Hy’s Law Cases Observed Part B, Multiple Ascending Doses Bilirubin vs. ALT Showed Bilirubin vs. AST Showed No Evidence of DILI Potential No Evidence of DILI Potential ALT: alanine aminotransferase; AST: aspartate aminotransferase; DILI: drug-induced liver injury; BIL: bilir

  59. Slide 59: Multiple Doses of IMU-856 Found to Have Favorable Safety and Tolerability

    Multiple Doses of IMU-856 in Healthy Human Subjects Found to Have a Favorable Safety and Tolerability Profile No IMP-related serious adverse events No dose-dependency in adverse events No maximum tolerated dose reached No trends for post-dose changes in any laboratory parameter No medically relevant

  60. Slide 60: Clinical Overview for IMU-856

    09 Clinical Overview for IMU-856 Summary Phase 1 Ongoing Phase 1 SAD/MAD Data in Part C Trial in Healthy Subjects Celiac Disease

  61. Slide 61: Phase 1 Clinical Trial of IMU-856

    Phase 1 Clinical Trial of IMU-856 Part C in Patients with Celiac Disease During Periods of GFD and Gluten Challenge Flow Chart of Part C in Celiac Disease Proof-of-Concept Study Day 1-28: Treatment IMU-856/placebo § Part C includes a well-controlled celiac disease Day 14-28: patient population, desi

  62. Slide 62: Phase 1 Clinical Trial of IMU-856

    Phase 1 Clinical Trial of IMU-856 Part C in Patients with Celiac Disease During Periods of GFD and Gluten Challenge Eligibility Criteria Key Objectives/Endpoints § Age 18 to 65 years (inclusive) Primary: § Biopsy proven diagnosis of celiac disease § Safety and tolerability for at least 12 months: Se

  63. Slide 63: Q&A Session and Closing

    10 Celiac Disease R&D Webcast Q&A Session and Closing

  64. Slide 64: IMU-856 Could Present a New and Innovative Approach for GI Diseases

    IMU-856 Could Present a New and Innovative Approach for the Treatment of Gastrointestinal Diseases § IMU-856 showed a favorable safety, tolerability and pharmacokinetic profile in the single and multiple ascending dose portions of the phase 1 clinical trial in healthy human subjects with no investig

  65. Slide 65: Thank You!

    Thank You! Immunic, Inc. Immunic AG 1200 Avenue of the Americas Lochhamer Schlag 21 New York City, NY 10036 82166 Gräfelfing (Munich) USA Germany Jessica Breu Head of IR & Communications Phone: +49-89-2080477-09 Email: ir@imux.com Immunic Australia Pty. Ltd. Web: www.imux.com Melbourne Australia 65

Immunic — Technical Presentation (February 2023) on 6ix